News | November 01, 2024
Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Developed in consultation with clinicians and patients for an enhanced user experience
Potential of Ayurveda’s contribution in global health system through various innovative practices
Subscribe To Our Newsletter & Stay Updated
